Participants with histologically confirmed UC. Upper and lower tract tumors are permitted and mixed histologies are permitted if UC is the predominant histology
ECOG Performance status score of 0 or 1.
Cohort 1: Have had progression or recurrence of urothelial cancer following receipt of platinum-containing regimen (cisplatin or carboplatin):
Received a first-line platinum-containing regimen in the metastatic setting or for inoperable locally advanced disease;
Or received neo/adjuvant platinum-containing therapy for localized muscle-invasive UC, with recurrence/progression >Cohort 1: In addition to above criterion, have had progression or recurrence of UC following receipt of an anti-PD-1 /PD-L1 therapy.
Cohort 2: Were ineligible for platinum-based therapy and have had progression or recurrence of UC after a first-line therapy for metastatic disease with anti-PD-1/PD-L1 therapy. Subject may not have received any platinum for treatment of recurrent, metastatic or advanced disease.
Cohort 3: Progression or recurrence of UC following a platinum -containing regimen in the metastatic setting, or progression or recurrence of UC within 12 months of completion of platinum-based therapy as neoadjuvant or adjuvant therapy.
Cohort 4 and 5: Cisplatin-eligible subject who has not received any therapy, specifically platinum-based chemotherapy in the metastatic or unresectable locally advanced setting
Cohorts 1 to 3: Adequate hematology without transfusion support,
Cohort 4 and 5: Total WBC count must be >4000 per mm3, ANC >1500 per mm3, platelets >100,000 per mcL, and hemoglobin >9 g/dL.
Cohort 4 and 5: Creatinine clearance of at least 50 mL/min calculated by Cockcroft–Gault formula or another validated tool. For subjects receiving cisplatin at 70 mg/m2 on Day 1 of every 21-day cycle, a creatinine clearance of least 60 mL/min calculated by Cockcroft –Gault formula or another validated tool is required. Subjects with creatinine clearance between 50 to 59 mL/min are to receive a split dose of cisplatin (35 mg/m2 Day 1 and Day 8 of every 21-day cycle).
Adequate renal and hepatic function.
Adequate hematologic parameters without transfusional support.
Creatinine clearance > Subjects must have a 3-month life expectancy.
Have measurable disease by CT or MRI as per RECIST 1.1 criteria.
Participant must be willing and able to comply with all protocol requirements
Has had a prior anti-cancer mAb within 4 weeks prior to study Day 1 or who has not recovered (i.e.,>Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., > Cohort 4 and 5: Refractory to platinum (i.e., relapsed >Requires concomitant medications that significantly interfere with ABCA1 transporter or UGT1A1 with no alternate option availble
Has an active second malignancy.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Has known active Hepatitis B or Hepatitis C
Cohorts 4 and 5: Hypersensitivity or anaphylaxis to cisplatin.
Cohorts 4 and 5: >Grade 2 hearing loss.
Cohorts 4 and 5: >Grade 2 peripheral neuropathy.
Has other concurrent medical or psychiatric conditions
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub